# Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca

> **NCT00128245** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 440 (—)

## Conditions studied

- Keratoconjunctivitis Sicca

## Interventions

- **DRUG:** Pimecrolimus
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT00128245
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 440 (—)
- **Last updated:** 2020-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00128245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00128245, "Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00128245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*